{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:49:45Z","timestamp":1788281385212,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Egyptian Russian University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Inflammatory bowel disease (IBD), consists of two primary types: Ulcerative Colitis (UC) and Crohn\u2019s Disease (CD). Infliximab (IFX) and Adalimumab (ADA) are frequently utilized in the management of moderate to severe cases of IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to assess the efficacy and safety of IFX and ADA in individuals diagnosed with moderate to severe IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This study is a prospective open-labeled randomized parallel study that included moderate to severe IBD patients treated with either IFX or ADA. A total of 56 patients participated, with 34 patients received IFX and 22 patients received ADA. Various measures, including Crohn\u2019s Disease Activity Index (CDAI), Mayo Score\/ Disease Activity Index (DAI), and C-reactive protein (CRP) levels, were taken at baseline and week 14 to assess the efficacy of the treatments. In addition, the levels of drugs and sTREM-1 were measured at 14\u00a0weeks. Patient safety was monitored throughout the study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the group received IFX, there was a notable decrease in CDAI (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.045), DAI (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.026), and CRP (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023 for CD, and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.021 for UC) levels. In addition, the group received ADA experienced a significant reduction in CDAI (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001), DAI (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.032), and CRP (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.018 for CD and\n                      <jats:italic>P<\/jats:italic>\n                      = 0.003 for UC) levels. Responders had higher drug concentrations than non-responders, notably IFX concentration was higher in responders with CD (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001) and UC (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). ADA concentration was higher in UC (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;= 0.001) and all CD patients responded to the treatment. The same trend was observed for sTREM-1 levels in CD and UC patients (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.042, and\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.015, respectively) in the IFX group. In UC patients treated with ADA, the level of sTREM-1 was significantly low (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both IFX and ADA have a good safety profile and deliver a beneficial clinical and laboratory response in moderate-severe IBD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      This study is registered on ClinicalTrials.gov under the identifier NCT05291039. (You can access the study at\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05291039\">https:\/\/clinicaltrials.gov\/study\/NCT05291039<\/jats:ext-link>\n                      (First Posted: March 22, 2022).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10787-024-01508-w","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:02:04Z","timestamp":1720569724000},"page":"3259-3269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients"],"prefix":"10.1007","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3253-8588","authenticated-orcid":false,"given":"Mahmoud E.","family":"Kamal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5983-3993","authenticated-orcid":false,"given":"Rehab H.","family":"Werida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahasen A.","family":"Radwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa R.","family":"Askar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamal A.","family":"Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marwa A.","family":"El-Mohamdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa S.","family":"Hagag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"1508_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20102529","author":"MA Aardoom","year":"2019","unstructured":"Aardoom MA, Veereman G, de Ridder L (2019) A Review on the use of anti-TNF in children and adolescents with inflammatory bowel disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20102529","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1508_CR2","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/ibd.20924","volume":"15","author":"W Afif","year":"2009","unstructured":"Afif W, Leighton JA, Hanauer SB, Loftus EV Jr, Faubion WA, Pardi DS et al (2009) Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab. Inflamm Bowel Dis 15(9):1302\u20131307","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"1508_CR3","first-page":"56","volume":"10","author":"A Afify","year":"2021","unstructured":"Afify A, Gado M, Gohar M, Wadea F (2021) Clinical and biochemical response of treatment with anti-TNF\u03b1 in egyptian IBD patients: zagazig university IBD clinic experience. Zagazig Univ Med J 10(4):56\u201378","journal-title":"Zagazig Univ Med J"},{"issue":"37","key":"1508_CR4","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.3748\/wjg.v27.i37.6231","volume":"27","author":"F Albader","year":"2021","unstructured":"Albader F, Golovics PA, Gonczi L, Bessissow T, Afif W, Lakatos PL (2021) Therapeutic drug monitoring in inflammatory bowel disease: the dawn of reactive monitoring. World J Gastroenterol 27(37):6231\u20136247","journal-title":"World J Gastroenterol"},{"issue":"10","key":"1508_CR5","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/apt.14030","volume":"45","author":"A Cholapranee","year":"2017","unstructured":"Cholapranee A, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN (2017) Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in crohn\u2019s disease and ulcerative colitis controlled trials. Aliment Pharmacol Ther 45(10):1291\u20131302","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"1508_CR6","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1002\/ibd.20956","volume":"15","author":"JF Colombel","year":"2009","unstructured":"Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J et al (2009) Adalimumab safety in global clinical trials of patients with crohn\u2019s disease. Inflamm Bowel Dis 15(9):1308\u20131319","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"1508_CR7","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/MEG.0b013e32836220ab","volume":"25","author":"W Da","year":"2013","unstructured":"Da W, Zhu J, Wang L, Lu Y (2013) Adalimumab for crohn\u2019s disease after infliximab treatment failure: a systematic review. Eur J Gastroenterol Hepatol 25(8):885\u2013891","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1508_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2147\/CLEP.S150030","volume":"10","author":"R Di Domenicantonio","year":"2018","unstructured":"Di Domenicantonio R, Trotta F, Cascini S, Agabiti N, Kohn A, Gasbarrini A et al (2018) Population-based cohort study on comparative effectiveness and safety of biologics in inflammatory bowel disease. Clin Epidemiol 10:203\u2013213","journal-title":"Clin Epidemiol"},{"key":"1508_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13880","author":"JD Doecke","year":"2017","unstructured":"Doecke JD, Hartnell F, Bampton P, Bell S, Mahy G, Grover Z et al (2017) Infliximab vs. adalimumab in crohn\u2019s disease: results from patients in an australian and new zealand observational cohort study. Aliment Pharmacol Ther. https:\/\/doi.org\/10.1111\/apt.13880","journal-title":"Aliment Pharmacol Ther"},{"issue":"22","key":"1508_CR10","doi-asserted-by":"publisher","first-page":"5318","DOI":"10.3390\/jcm10225318","volume":"10","author":"JP Gisbert","year":"2021","unstructured":"Gisbert JP, Chaparro M (2021) Primary failure to an anti-TNF Agent in inflammatory bowel disease: switch (to a second anti-TNF agent) or swap (for another mechanism of action)? J Clin Med 10(22):5318","journal-title":"J Clin Med"},{"issue":"1","key":"1508_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3349\/ymj.2020.61.1.48","volume":"61","author":"M Han","year":"2020","unstructured":"Han M, Jung YS, Cheon JH, Park S (2020) Comparison of real-world outcomes of infliximab versus adalimumab in biologic-naive korean patients with ulcerative colitis: a population-based study. Yonsei Med J 61(1):48\u201355","journal-title":"Yonsei Med J"},{"issue":"1","key":"1508_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12664-018-0922-1","volume":"38","author":"N Kamat","year":"2019","unstructured":"Kamat N, Kedia S, Ghoshal UC, Nehra A, Makharia G, Sood A et al (2019) Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: a multicenter study. Indian J Gastroenterol 38(1):44\u201354","journal-title":"Indian J Gastroenterol"},{"issue":"5","key":"1508_CR13","doi-asserted-by":"publisher","first-page":"765","DOI":"10.5114\/aoms.2013.38670","volume":"9","author":"P Kawalec","year":"2013","unstructured":"Kawalec P, Mikrut A, Wisniewska N, Pilc A (2013) Tumor necrosis factor-alpha antibodies (infliximab, adalimumab and certolizumab) in crohn\u2019s disease: systematic review and meta-analysis. Arch Med Sci 9(5):765\u2013779","journal-title":"Arch Med Sci"},{"key":"1508_CR14","doi-asserted-by":"publisher","first-page":"175628482096130","DOI":"10.1177\/1756284820961302","volume":"13","author":"SY Kim","year":"2020","unstructured":"Kim SY, An S, Park DK, Kwon KA, Kim KO, Chung JW et al (2020) Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents. Therap Adv Gastroenterol 13:1756284820961302","journal-title":"Therap Adv Gastroenterol"},{"issue":"4","key":"1508_CR15","first-page":"56","volume":"10","author":"Y Kutlu","year":"2021","unstructured":"Kutlu Y, Toprak \u0130, G\u00f6kden Y, Eruzun H, Arman Y, Ayd\u0131n Yoldemir \u015e et al (2021) THE relationship between strem-1 and activation of inflammatory bowel diseases. \u0130stanbul T\u0131p Fak\u00fcltesi Dergisi. 10(4):56\u201378","journal-title":"\u0130stanbul T\u0131p Fak\u00fcltesi Dergisi."},{"issue":"2","key":"1508_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.5009\/gnl19433","volume":"15","author":"YI Lee","year":"2021","unstructured":"Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH (2021) Comparison of long-term outcomes of infliximab versus adalimumab treatment in biologic-naive patients with ulcerative colitis. Gut Liver 15(2):232\u2013242","journal-title":"Gut Liver"},{"key":"1508_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.coph.2020.10.003","volume":"55","author":"C Liefferinckx","year":"2020","unstructured":"Liefferinckx C, Cremer A, Franchimont D (2020) Switching biologics used in inflammatory bowel diseases: how to deal with in practice? Curr Opin Pharmacol 55:82\u201389","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"1508_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","volume":"13","author":"C Maaser","year":"2019","unstructured":"Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V et al (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 13(2):144\u2013164","journal-title":"J Crohns Colitis"},{"issue":"32","key":"1508_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007800","volume":"96","author":"T Mizoshita","year":"2017","unstructured":"Mizoshita T, Katano T, Tanida S, Hirano A, Miyaki T, Ozeki K et al (2017) Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy. Medicine (baltimore) 96(32):e7800","journal-title":"Medicine (baltimore)"},{"issue":"5","key":"1508_CR20","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1007\/s10620-018-4952-4","volume":"63","author":"T Mogilevski","year":"2018","unstructured":"Mogilevski T, Sparrow MP (2018) Infliximab versus adalimumab in patients with biologic-na\u00efve crohn\u2019s disease: is the difference real? Dig Dis Sci 63(5):1094\u20131096","journal-title":"Dig Dis Sci"},{"key":"1508_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.09.021","author":"OH Nielsen","year":"2022","unstructured":"Nielsen OH, Gubatan JM, Juhl CB, Streett SE, Maxwell C (2022) Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2020.09.021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"1508_CR22","volume":"13","author":"OE Okobi","year":"2021","unstructured":"Okobi OE, Udoete IO, Fasehun OO, Okobi T, Evbayekha EO, Ekabua JJ et al (2021) A review of four practice guidelines of inflammatory bowel disease. Cureus 13(8):e16859","journal-title":"Cureus"},{"issue":"4","key":"1508_CR23","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.gtc.2020.08.003","volume":"49","author":"BS Pabla","year":"2020","unstructured":"Pabla BS, Schwartz DA (2020) Assessing severity of disease in patients with ulcerative colitis. Gastroenterol Clin North Am 49(4):671\u2013688","journal-title":"Gastroenterol Clin North Am"},{"key":"1508_CR24","doi-asserted-by":"publisher","first-page":"204062231983844","DOI":"10.1177\/2040622319838443","volume":"10","author":"K Papamichael","year":"2019","unstructured":"Papamichael K, Lin S, Moore M, Papaioannou G, Sattler L, Cheifetz AS (2019) Infliximab in inflammatory bowel disease. Ther Adv Chronic Dis 10:2040622319838443","journal-title":"Ther Adv Chronic Dis"},{"key":"1508_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12206577","author":"S Patel","year":"2023","unstructured":"Patel S, Yarur AJ (2023) A Review of therapeutic drug monitoring in patients with inflammatory bowel disease receiving combination therapy. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12206577","journal-title":"J Clin Med"},{"issue":"6","key":"1508_CR26","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1093\/ibd\/izy320","volume":"25","author":"N Plevris","year":"2019","unstructured":"Plevris N, Lyons M, Jenkinson PW, Chuah CS, Merchant LM, Pattenden RJ et al (2019) Higher adalimumab drug levels during maintenance therapy for crohn\u2019s disease are associated with biologic remission. Inflamm Bowel Dis 25(6):1036\u20131043","journal-title":"Inflamm Bowel Dis"},{"key":"1508_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627535","volume":"12","author":"MM Prins","year":"2021","unstructured":"Prins MM, Verstockt B, Ferrante M, Vermeire S, Wildenberg ME, Koelink PJ (2021) Monocyte TREM-1 levels associate with anti-TNF responsiveness in IBD through autophagy and fcgamma-receptor signaling pathways. Front Immunol 12:627535","journal-title":"Front Immunol"},{"key":"1508_CR28","doi-asserted-by":"publisher","first-page":"300","DOI":"10.22159\/ajpcr.2017.v10i3.16213","volume":"10","author":"B Razzaq","year":"2017","unstructured":"Razzaq B (2017) Efficacy and safety of adalimumab versus infliximab in patients suffered from moderate to severe active ulcerative colitis. Asian J Pharm Clin Res 10:300\u2013307","journal-title":"Asian J Pharm Clin Res"},{"issue":"2","key":"1508_CR29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.25122\/jml-2018-0075","volume":"12","author":"SS Seyedian","year":"2019","unstructured":"Seyedian SS, Nokhostin F, Malamir MD (2019) A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J Med Life 12(2):113\u2013122","journal-title":"J Med Life"},{"key":"1508_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s43162-022-00115-x","author":"MAA Shamkh","year":"2022","unstructured":"Shamkh MAA, Sakr MA, Abd Alaty WH, Kamel SY, Eltabbakh MM, Sherief AF et al (2022) A decade of inflammatory bowel disease: a single center experience in Egypt. The Egyptian Journal of Internal Medicine. https:\/\/doi.org\/10.1186\/s43162-022-00115-x","journal-title":"The Egyptian Journal of Internal Medicine"},{"issue":"12","key":"1508_CR31","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","volume":"6","author":"S Singh","year":"2021","unstructured":"Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R et al (2021) Comparative efficacy and safety of biologic therapies for moderate-to-severe crohn\u2019s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol 6(12):1002\u20131014","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"1508_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-2036.17.s2.17.x","volume":"17","author":"R Sostegni","year":"2003","unstructured":"Sostegni R, Daperno M, Scaglione N, Lavagna A, Rocca R, Pera A (2003) Review article: crohn\u2019s disease: monitoring disease activity. Aliment Pharmacol Ther 17(Suppl 2):11\u201317","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1508_CR33","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","volume":"13","author":"A Sturm","year":"2019","unstructured":"Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T et al (2019) ECCO-ESGAR guideline for diagnostic assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 13(3):273\u2013284","journal-title":"J Crohns Colitis"},{"issue":"7","key":"1508_CR34","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.jfma.2018.07.005","volume":"118","author":"HJ Su","year":"2019","unstructured":"Su HJ, Chiu YT, Chiu CT, Lin YC, Wang CY, Hsieh JY et al (2019) Inflammatory bowel disease and its treatment in 2018: global and taiwanese status updates. J Formos Med Assoc 118(7):1083\u20131092","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"1508_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1586\/17474124.2015.1024657","volume":"9","author":"K Thorlund","year":"2015","unstructured":"Thorlund K, Druyts E, Toor K, Mills EJ (2015) Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol 9(5):693\u2013700","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"1508_CR36","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1097\/MEG.0000000000002087","volume":"33","author":"A Tursi","year":"2021","unstructured":"Tursi A, Mocci G, Lorenzetti R, Allegretta L, Brandimarte G, Cassieri C et al (2021) Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients. Eur J Gastroenterol Hepatol 33(5):670\u2013679","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"1508_CR37","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1136\/gutjnl-2018-316845","volume":"68","author":"B Verstockt","year":"2019","unstructured":"Verstockt B, Verstockt S, Blevi H, Cleynen I, de Bruyn M, Van Assche G et al (2019) TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated crohn\u2019s disease patients? Gut 68(8):1531\u20131533","journal-title":"Gut"},{"issue":"1","key":"1508_CR38","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1186\/s12884-022-05191-z","volume":"22","author":"H Wang","year":"2022","unstructured":"Wang H, Hu Y, Chen F, Shen M (2022) Comparative safety of infliximab and adalimumab on pregnancy outcomes of women with inflammatory bowel diseases: a systematic review & meta-analysis. BMC Pregnancy Childbirth 22(1):854","journal-title":"BMC Pregnancy Childbirth"},{"issue":"18","key":"1508_CR39","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.12998\/wjcc.v10.i18.6091","volume":"10","author":"HH Yang","year":"2022","unstructured":"Yang HH, Huang Y, Zhou XC, Wang RN (2022) Efficacy and safety of adalimumab in comparison to infliximab for crohn\u2019s disease: a systematic review and meta-analysis. World J Clin Cases 10(18):6091\u20136104","journal-title":"World J Clin Cases"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-024-01508-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-024-01508-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T12:06:00Z","timestamp":1726920360000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-024-01508-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1508"],"URL":"https:\/\/doi.org\/10.1007\/s10787-024-01508-w","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"18 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest were declared by the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}}]}}